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Abstract The central nervous system (CNS) is capable of
gathering information on the body’s nutritional state and it
implements appropriate behavioral and metabolic respon-
ses to changes in fuel availability. This feedback signaling
of peripheral tissues ensures the maintenance of energy
homeostasis. The hypothalamus is a primary site of con-
vergence and integration for these nutrient-related
feedback signals, which include central and peripheral
neuronal inputs as well as hormonal signals. Increasing
evidence indicates that glucose and lipids are detected by
specialized fuel-sensing neurons that are integrated in these
hypothalamic neuronal circuits. The purpose of this review
is to outline the current understanding of fuel-sensing
mechanisms in the hypothalamus, to integrate the recent
findings in this field, and to address the potential role of
dysregulation in these pathways in the development of
obesity and type 2 diabetes mellitus.
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Introduction
Precise control of energy intake, storage, and expenditure
is indispensable in keeping body weight and blood glucose
concentrations within physiological ranges. Dysregulation
of these homeostatic processes is associated with the
development of obesity and type 2 diabetes mellitus;
however, the exact underlying mechanisms leading to these
diseases are still not fully elucidated.
Communication of the body’s nutritional state by feed-
back signaling of peripheral organs to the CNS and the
appropriate behavioral and metabolic responses initiated by
the brain are pivotal processes in maintaining energy
homeostasis. The hypothalamus, and in particular the
arcuate nucleus (the most external hypothalamic nucleus),
are located close to the median eminence, a site charac-
terized by a discontinuous blood–brain barrier, allowing for
direct access of circulating hormones and nutrients to the
CNS [1]. Thus, the hypothalamus is a potential primary site
of convergence and integration for nutrient-related signals,
which include central and peripheral neuronal inputs as
well as hormonal signals [2]. Besides fuel-communicating
hormones such as insulin and leptin, increasing evidence
indicates that glucose and lipids are detected by specialized
fuel-sensing neurons that are incorporated in critical
hypothalamic neuronal circuits. Hence, circulating nutri-
ents cooperate with hormones, such as insulin, leptin, and
ghrelin, to regulate the activity of distinct neuron popula-
tions that control food intake, energy expenditure, and
glucose homeostasis. Thus, this review aims to provide an
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updated view of the pathways of glucose and lipid sensing
in the hypothalamus and to delineate the contribution of
impaired neuronal nutrient sensing to the etiology of
obesity and type 2 diabetes mellitus.
Central glucose sensing
Glucose sensing in the hypothalamus
The earliest demonstration that the brain is involved in the
control of blood glucose levels was provided by Claude
Bernard, who showed that hypothalamic lesions induce
hyperglycemia in dogs [3]. In 1953, John Mayer proposed
that cells located in the hypothalamus could be specialized
to monitor variations in blood glucose concentrations and
further postulated that these cells translate these variations
in glucose concentrations in electrical or chemical signals
that control feeding behavior [4]. About 10 years later, two
groups indeed demonstrated the presence of such special-
ized glucose-sensing neurons by electrophysiological
analysis of hypothalamic slides. Anand et al. and Oomura
et al. independently identified hypothalamic neurons that
are able to modulate their firing activity in response to
changes in extracellular glucose concentrations [5, 6].
Essentially two different types of glucose-responsive
neurons can monitor changes in blood glucose levels:
glucose-excited (GE) neurons, whose firing rate is
increased by elevation of extracellular glucose concentra-
tions, and glucose-inhibited (GI) neurons, which are
activated when glucose concentrations decrease [7]. Both
types of neurons are widely distributed throughout the
brain but highly represented in hypothalamic nuclei, which
are involved in the control of energy homeostasis. GE
neurons are most abundant in the ventromedial nucleus
(VMN), the arcuate nucleus (ARC), and the paraventricular
nucleus (PVN), whereas GI neurons are mostly located in
the lateral hypothalamus (LH), the median ARC, and the
PVN [8]. In the ARC, the presence of GE and GI neurons
responsive to glucose over either a low range (0–5 mM) or
a high range (5–20 mM) of glucose concentrations has
been described, the latter are referred to as HGE (high
glucose excited) or HGI (high glucose inhibited) neurons,
respectively [9, 10].
GE and GI neurons are also present in the brain stem, in
particular in the area postrema (AP), the nucleus of solitary
tract (NTS), and the dorsal motor nucleus of the vagus
(DMNX) [11]. The NTS represents a critical node of
convergence that integrates various signals from the
periphery and relays them to the hypothalamus. Neurons in
the NTS are sensitive to small variations in blood glucose
concentrations and may regulate the activity of hypotha-
lamic neurons since they project widely into hypothalamic
nuclei implicated in the control of blood glucose levels and
food intake [12].
Neuronal circuits of the ARC are among the best-studied
systems in the central regulation of energy homeostasis.
Key players are two functionally opposing neuron popu-
lations, the agouti-related peptide/neuropeptide Y (AgRP/
NPY)-expressing and the proopiomelanocortin and
cocaine-and amphetamine-related transcript (POMC/
CART)-expressing neurons [13, 14]. The anorectic POMC/
CART neurons express POMC as a precursor peptide,
which, dependent on the cell-type specific expression pat-
tern of prohormone convertases, is processed to different
bioactive products [15]. Among these are the melanocyte-
stimulating hormones (a-, b-, and c-MSH). a-MSH and
b-MSH reduce food intake and increase energy expenditure
both in animals and in humans [16–18]. a-MSH and
b-MSH act on melanocortin receptor (MC-R) types 3 and
4, which are expressed in the ARC, the PVN, LH, VMN,
and dorsomedial hypothalamus [19, 20]. The second key
neuron population in the ARC is formed by the orexigenic
AgRP/NPY neurons. NPY is a potent stimulator of food
intake and it reduces energy expenditure [21, 22]. AgRP
acts as an inverse agonist of the MC3/4-R and prevents the
anorectic effect of a-MSH [23]. Besides their regulation by
hormones, such as insulin, leptin, and ghrelin, these both
types of neurons represent prototypic glucose-sensing
neurons. In particular, through electrophysiological
recordings of identified, genetically marked neuron popu-
lations, it has been demonstrated that increasing
extracellular glucose levels inhibit AgRP/NPY neurons and
excite POMC neurons [24–27].
AgRP/NPY and POMC neurons extend broad projec-
tions to various brain regions including the LH that harbors
two other populations of glucose-sensing neurons, the
orexin-expressing and the melanin-concentrating hormone
(MCH) neurons. Orexin neurons are inhibited and MCH
neurons are excited by glucose, in addition both popula-
tions receive inputs from AgRP/NPY and POMC neurons
[28–30].
Molecular mechanisms of glucose sensing
Since GE neurons increase their firing activity when
extracellular glucose rises, they share similarity to pan-
creatic b-cells [31–33]. Glucose signaling in b-cells
requires glucose uptake by the low-affinity glucose trans-
porter type 2 (GLUT2), glucose phosphorylation by
glucokinase, the rate-limiting enzyme of glycolysis, and
subsequent metabolism of glucose to increase intracellular
ATP concentration [34]. This in turn leads to closure of
ATP-sensitive potassium (KATP) channels [35], membrane
depolarization, and the entry of Ca2?, which triggers
insulin secretion. Thus, many studies have evaluated the
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role of GLUT2, glucokinase, and the KATP channel sub-
units SUR1, SUR2, and Kir6.2 in central glucose sensing.
GLUT2 is expressed in hypothalamic nuclei where
glucose-sensitive neurons are present [36–39]. In trans-
genic mice, central GLUT2 has been shown to be involved
in the counter-regulatory response to hypoglycemia [40].
In the pancreatic b-cell, glucokinase is the critical reg-
ulator of glycolytic production of ATP and KATP channel
activity [41]. The pancreatic form of glucokinase is also
present in brain areas involved in glucose sensing and in
about 70% of GE neurons glucokinase mRNA is detectable
[37, 42–44]. Indeed, glucokinase has been shown to regu-
late the ability of GE neurons to sense glucose [32, 37, 42,
45]. In addition, the selective down-regulation of glucoki-
nase in primary VMH neuronal cultures led to selective
loss of glucose sensing [46].
KATP channels play a fundamental role since they link
changes in glucose metabolism to electrical activity [47]
and expression has been demonstrated throughout the
brain, including hypothalamic regions involved in glucose
sensing [48–51]. Using single-cell RT-PCR to analyze
glucose-sensing neurons, investigators have shown the
expression of the KATP channel subunits SUR1 and Kir6.2
in the hypothalamus [37]. In addition, electrophysiological
studies have demonstrated that pharmacological inhibition
or activation of KATP channels can alter the response of GE
neurons to changes in ambient glucose in vitro and in vivo
[32, 48, 52–57]. In line with a role in glucose sensing, the
expression of a mutated version of the KATP subunit Kir6.2
(resulting in dramatically reduced ATP sensitivity) spe-
cifically in POMC neurons blunted glucose sensing.
Interestingly, obesity-induced POMC glucose insensitivity
is mediated by the mitochondrial protein uncoupling pro-
tein 2 (UCP2), which impairs glucose-stimulated ATP
production and thus KATP channel closure, while its genetic
deletion or pharmacological inhibition reversed the
phenotype [58].
Taken together, there is considerable evidence that
similar to pancreatic b-cells, an increase in extracellular
glucose raises ATP levels in GE neurons, which leads to
the closure of KATP channels [49, 53, 57, 59, 60], and thus
plasma membrane depolarization. Subsequent Ca2? entry
through voltage-gated channels finally increases neuronal
activity and neurotransmitter secretion [61, 62] (Fig. 1a).
There is however also indication that neuronal glucose
sensing could be independent of KATP channels [9], glu-
cokinase [63], or GLUT2 [37]. For instance, the activation
of an ARC GE neuron population by glucose seems to
depend on the glucose-regulated activity of transient
response potential (TRP) channels [9]. Moreover, a recent
study identified the heterodimeric G-protein-coupled sweet
receptor T1R2/T1R3 as a candidate membrane-bound brain
glucose sensor that allows neurons to change firing rates
independently of intracellular glucose metabolism [64].
Fig. 1 Potential mechanisms of glucose sensing in hypothalamic
neurons. a An increase in extracellular glucose and/or lactate raises
the ATP/ADP ratio in GE neurons, which leads to the closure of KATP
channels and thus plasma membrane depolarization. Subsequent Ca2?
entry through voltage-gated channels finally increases neuronal
activity and neurotransmitter secretion. b In GI neurons, suppression
of neurotransmitter secretion at elevated glucose might be caused by
an ATP-mediated increase in Na?–K?-ATPase activity and/or
inhibition of AMPK, which in turn opens Cl- or other ion channels.
In other GI neurons, glucose-induced hyperpolarization might be due
to K? channels opened by an ATP- and AMPK-independent
mechanism
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In GI neurons, the mechanism linking a decrease in
glucose concentrations to increased firing activity is less
clear (Fig. 1b). An early study proposed that suppression
of firing activity at elevated glucose levels might be
controlled by the increase in the ATP-to-ADP ratio,
which leads to an increase in Na?–K?-ATPase activity
[8, 65]. A further study indicated that the opening of
plasma membrane Cl- channels at elevated glucose con-
centrations leads to cell hyperpolarization and inhibition
of VMN and ARC GI neurons [27, 54, 63]. For GI orexin
neurons, it has been shown that tandem-pore K? channels
could mediate their inhibition by glucose [66], however a
recent study demonstrated that glucose inhibition persists
in orexin neurons lacking tandem-pore K? channels [67].
Orexin neurons further exhibit carbohydrate selectivity
and can operate independently of glucose metabolism
[68]. Moreover, a distinct group of orexin neurons
exhibits only transient inhibitory responses to sustained
rises in glucose levels due to time-dependent recovery
from inhibition via adaptive closure of leak-like K?
channels, presumably the same channels as those acti-
vated by glucose [69]. This adaptive glucose sensing
allows orexin cell firing to maintain sensitivity to small
fluctuations in glucose levels despite large background
levels of glucose.
Changes in AMP-activated protein kinase (AMPK)
activity are likely to mediate some effects of glucose on
VMN and ARC GI neurons [26, 70]. AMPK is activated in
response to a rise in intracellular AMP levels, which
increase under conditions of cellular stress or energy
deficiency, such as hypoxia, ischemia, and glucose depri-
vation [71, 72]. Activated AMPK acts to switch off energy-
consuming anabolic processes and switch on energy
producing catabolic processes [73] and has therefore been
suggested as an important glucose sensor. As shown in cell
lines and ex vivo hypothalamic tissue, AMPK activity is
stimulated by low glucose levels and AMPK activation
increases orexigenic AgRP expression [74]. This study also
demonstrated that small changes in hypothalamic glucose
levels in the physiological range of 1–5 mM altered cel-
lular ATP levels sufficiently to induce AMPK activation
and gene expression. Recently, the cAMP response element
binding protein (CREB) co-activator CRTC2 was identified
as a new hypothalamic AMPK target, linking hypothalamic
glucose sensing with cAMP response element (CRE) gene
expression [75]. Mechanistically, it is possible that AMPK
activation in GI neurons leads to the phosphorylation and
thereby inactivation of plasma membrane Cl- and/or other
ion channels [54], leading to depolarization, and activation
of the neuron. Consistently, studies of Murphy et al. [76]
suggest that in VMH GI neurons activated AMPK phos-
phorylates neuronal nitric oxide synthase (nNOS) leading
to nitric oxide production, which in turn amplifies AMPK
activation and thereby closure of the Cl- channel cystric
fibrosis transmembrane regulator (CFTR).
Since glucokinase mRNA is expressed in about 40% of
GI neurons it may also hold a regulatory role in these
neurons [42, 46], although it seems that AMPK activity
plays a predominant role in GI neuronal glucose sensing.
Glucose-sensing neurons do not perform their function
in isolation. They are surrounded and provided with met-
abolic fuels by glia cells. Astrocytes readily take up and
store glucose as glycogen, which is hydrolyzed to release
lactate into the extracellular space when glucose is scarce.
Extracellular lactate is taken up by neurons and converted
to pyruvate, which is then oxidized in mitochondria to
provide ATP [37, 77, 78]. By this mechanism, lactate is
able to trigger KATP channel closure [79, 80] and thereby
reverse the inhibition of GE activity, which occurs at low
ambient glucose levels [63]. Importantly, levels of the
lactate/monocarboxylate transporters, which are very low
in pancreatic b-cells [81, 82], appear to be relatively high
in the hypothalamus [78, 79]. The role of astrocytes in
central glucose sensing is further supported by the already-
mentioned finding that re-expression of GLUT2 in astro-
cytes was sufficient to rescue the phenotype of mice
lacking central GLUT2 [40]. However, it is conceivable
that depending on substrate availability, one or more glu-
cose-sensing pathways are used by different neuronal
populations.
Physiological functions regulated by central glucose
sensing
Food intake
The role of glucose in the regulation of feeding has early
been postulated [4, 83]. It has been shown that initiation of
feeding is preceded by a drop in blood glucose concen-
tration [84] and if this is prevented by glucose infusion,
then initiation of feeding is suppressed [85]. In addition,
intrahypothalamic infusion of glucose leads to a decrease
in food intake and body weight [86–88]. Induction of
cellular glucoprivation by central administration of
2-deoxy-D-glucose (2-DG), a glucose analogue able to
inhibit glucose metabolism, however, induces food intake
[89, 90]. In particular, brain stem areas such as the DMNX
and NTS appear to be the primary site of glucoprivation
detection, since direct injections of 5-thioglucose (5-TG), a
2-DG analogue, into these areas stimulated food intake
[89, 91] whereas direct injection of 2-DG into the VMH or
LH failed to activate feeding.
As already mentioned, glucose-sensitive neurons of the
brain stem project widely into the hypothalamus, in par-
ticular the PVN and the ARC. Destruction of these
neuronal projections by immunotoxins suppressed the
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effect of peripheral 2-DG administration on food intake
[92] and on the regulation of NPY and AgRP expression
[93]. The pivotal role of AgRP/NPY-expressing neurons in
the acute regulation of feeding in adult mammals has been
impressively demonstrated by two independent studies
using diphtheria-toxin-mediated ablation of this neuron
population [13, 94]. However, the extent to which these
neurons contribute to glucose-induced inhibition of feeding
is still unclear. When Luquet et al. [95] destroyed AgRP/
NPY neurons in neonatal mice, they found that feeding
responses to glucoprivation were unaffected. The same
group previously showed that in contrast to starvation
induced upon elimination in adult mice, neonatal destruc-
tion of these neurons has minimal effects on feeding in
general, which illustrates the impressive plasticity of this
circuitry [94]. Thus, it is still possible that glucose-induced
inhibition of AgRP/NPY neurons has profound effects on
feeding when the brain is allowed to develop normally.
On a molecular level, many of the critical components
of glucose sensing have been demonstrated to be involved
in the regulation of food intake. For instance, central
GLUT2 expression has been linked to feeding regulation
by knockdown experiments using antisense oligonucleo-
tides as well as targeted disruption of the Glut2 gene.
Injection of antisense oligonucleotides in the ARC
decreased food intake and led to resistance towards the
effects of 2-DG on feeding behavior [96]. In the GLUT2-
null mice, ad libitum feeding as well as refeeding after a
24 h fast was higher than in controls [97]. Moreover,
during the fast-to-refed transition, expression of the orex-
igenic (NPY, AgRP) and anorexigenic (POMC, CART)
neuropeptides was dysregulated in the absence of GLUT2.
This was directly attributed to the loss of central glucose
sensing, as intracerebroventricular (ICV) glucose in fasted
GLUT2-null mice failed to reduce NPY and to increase
POMC expression. In parallel in GLUT2 knockdown ani-
mals, feeding responses to ICV glucose or 2-DG were also
lost. In humans, a genetic variation in GLUT2 is associated
with a higher daily intake of sugars [98].
These data indicate that GLUT2 is required for physi-
ological control of feeding by glucose. However, attempts
to localize GLUT2 in the brain so far failed to show its
expression in POMC or NPY neurons, although it was
found to be associated with other hypothalamic and brain
stem structures [36–38, 99, 100] and it was further shown
to be expressed in astrocytes, endothelial cells, and tany-
cytes of the third ventricle [101–103]. Thus, the regulation
of orexigenic and anorexigenic peptide expressions by
GLUT2-dependent sensors may be controlled indirectly,
probably by glucose-sensitive neurons located in other
brain regions, such as the brain stem.
Haploinsufficiency for glucokinase in mice gave rise to
effects similar to those observed during hypoglycemia, i.e.,
increased food intake and a hypothalamic gene expression
profile similar to fasted mice (increased hypothalamic NPY
mRNA and reduced hypothalamic POMC mRNA), indi-
cating impaired glucose sensing in these animals [104].
Evidence for a role of KATP channels in the control of
feeding comes from the study of mice with inactivation of
the Kir6.2 gene as well as mice with constitutive active
KATP channels exclusively in POMC neurons. Whereas,
Kir6.2-null mice display a smaller feeding response to
intraperitoneal 2-DG administration than control mice [53],
mice expressing a constitutively active Kir6.2 subunit in
POMC cells exhibited normal feeding behavior despite the
complete unresponsiveness of these neurons to elevations
in extra-cellular glucose concentration [58]. However,
studies in POMC cells with constitutive active phosphati-
dylinositol 3,4,5-triphosphate (PIP3) formation, mimicking
insulin-stimulated activation of the PI3 kinase pathway
(see below), demonstrated an effect of constitutive active
KATP channels on feeding behavior [105]. In the hypo-
thalamus, PIP3 has been shown to regulate cell excitability
by binding to the regulatory subunit of KATP channels and
modulating their activity by at least three different mech-
anisms: (i) by increasing the probability that KATP channels
are open, which indirectly lowers the ability of ATP to
inhibit the channels, (ii) by directly decreasing ATP
binding to the channel, and (iii) by modulating the local
cytoskeleton in the vicinity of the channels [106–109]. We
demonstrated that augmented PIP3-dependent KATP chan-
nel activation leads to electrical silencing of POMC
neurons and consequently to hyperphagia [105].
The role of the metabolic sensor AMPK in feeding con-
trol was addressed by generating mice lacking AMPKa2 in
either POMC (POMCa2KO) or AgRP/NPY (AgRPa2KO)
neurons [110]. In both neuron populations, inactivation of
AMPK suppressed the glucose-mediated regulation of firing
activity, indicating that AMPK function is necessary for
glucose sensing in these neuron populations. Absence of this
enzyme from POMC neurons led to increased feeding in
response to fasting, an imbalance in the expression of
hypothalamic orexigenic and anorexigenic peptides, favor-
ing an orexigenic output and body weight gain. Inactivation
of AMPK in AgRP/NPY neurons led to a modest reduction
of body weight, which developed after 3 months of age.
However, this was not associated with detectable differences
in feeding or in orexigenic and anorexigenic neuropeptide
expressions. The molecular mechanism how AMPK allows
POMC and AGRP/NPY neurons to sense glucose and thus
alters their neuronal excitation is currently unknown.
Energy expenditure
It has been known for several years that infusions of
glucose can both increase general sympathetic activity
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(as evidenced by increased plasma norepinephrine levels)
[111, 112] and produce an increase in thermogenesis,
which is partly due to such sympathetic activation [113].
These effects of glucose were independent of insulin’s
well-known function as activator of sympathetic activity,
since glucose evoked these effects in insulin-deficient
animals [112] as well as after direct infusion into the
forebrain via the carotid artery (without altering plasma
insulin levels) [114, 115]. Such forebrain infusions activate
neurons in several hypothalamic areas known to contain
glucose-sensing neurons such as those in the PVN
[51, 116]. The thermogenic effects of glucose are probably
also mediated by hypothalamic glucose-sensing neurons,
since intracarotid and direct injections of glucose into the
VMH and PVN produce increased activity in the sympa-
thetic efferents to brown adipose tissue [117, 118], and
mice lacking AMPK in POMC neurons developed obesity
partially caused by reduced resting metabolic rate with
concomitant downregulation of brown adipose tissue
thermogenic genes [110].
Hepatic glucose production
Similar to what is seen in the central regulation of energy
intake and expenditure, the brain also directly responds to
changes in fuel availability to maintain glucose homeo-
stasis. In the regulation of blood glucose levels, the liver
plays a pivotal role. During times of starvation, breakdown
of hepatic glycogen stores (glycogenolysis) and hepatic de
novo synthesis of glucose (gluconeogenesis) from precur-
sors such as lactate, gluconeogenic amino acids, and
glycerol provide the organism with glucose. On the other
hand, when food (and consequently glucose) are available,
hepatic glucose production (HGP) needs to be suppressed.
Besides being subjected to tight hormonal control [119],
these processes are also directly regulated by glucose. In
response to changing concentrations of hypothalamic
glucose, gluconeogenesis, glycogenolysis, and with it total
HGP are significantly reduced [80]. The fact that besides
glucose also lactate is able to inhibit glucose production
when administered directly into the ARC suggests that
mitochondrial oxidation is necessary for the CNS to
respond to glucose. The finding that pharmacologically
blocking lactate dehydrogenase inhibited both lactate- and
glucose-induced decrease in HGP, further supported this
notion. In contrast, the activation of pyruvate dehydroge-
nase mimicked the inhibition of HGP [80]. These findings
suggest that the neuronal tricarboxylic acid cycle may
function as a biochemical sensor for carbohydrate avail-
ability, which in turn modulates HGP. The effects of
glucose and lactate seem to depend critically on the acti-
vation of KATP channels. In fact, the suppressive effect of
intra-ARC infusions of glucose or lactate on HGP is
blocked by a concomitant infusion of glibenclamide, a KATP
channel blocker [80, 120]. Thus, besides feeding behavior,
glucose homeostasis is also linked with KATP channel
function in glucose-sensing neurons. In a more recent study,
Kokorovic et al. demonstrated that hypothalamic sensing of
circulating lactate levels also regulates glucose production
[121]. In the presence of physiologically relevant increases
in the levels of plasma lactate (intravenous injection),
inhibition of central lactate-sensing mechanisms by lactate
dehydrogenase inhibitor oxamate or KATP channel blocker
glibenclamide increased glucose production. Furthermore,
direct administration of oxamate into the mediobasal
hypothalamus increased glucose production in the presence
of a similar elevation of circulating lactate.
Interestingly, central glucose and lactate sensing seems
to also affect hepatic lipid metabolism. ICV administration
of glucose or lactate was found to lower circulating lipid
concentrations and, more importantly, hepatic lipid pro-
duction [122]. Again, pharmacologically blocking either
lactate dehydrogenase or KATP channel function blunted
these effects [122].
Counter-regulatory processes
Glucose sensing in the brain is also implicated in the
counter-regulatory response to hypoglycemia. In particular,
this involves the activation of glucagon secretion from
pancreatic a-cells and catecholamines from adrenal glands
[123–125].
Experimentally, counter-regulation is activated either by
insulin-induced hypoglycemia or by injection of 2-DG or
5-TG to induce cellular glucoprivation. In both conditions,
afferent neurons located in the abdominal regions relay the
information to the brain stem and the hypothalamus, which
can also be directly activated by hypoglycemia or the
glucoprivic signal. The role of central glucose sensing in
the control of counter-regulation can be evidenced by
intracarotid glucose infusion, which blocks hypoglycemia-
induced secretion of counter-regulatory hormones
[126, 127], or by ICV injection of 2-DG, which stimulates
glucagon and catecholamine secretion [128]. The
involvement of hypothalamic nuclei, in particular the
VMH, has been assessed in lesion studies and by phar-
macological or genetic interference with glucose detection
systems [127]. For instance, glucagon secretion can be
induced by direct injection of 2-DG in the VMH [128], or,
in contrast, hypoglycemia-induced glucagon secretion can
be suppressed by direct VMH injection of glucose [129]. In
a series of studies, Chan et al. [130] demonstrated that
modulation of the c-aminobutyric acid (GABA) inhibitory
tone in the VMH modifies the magnitude of glucagon
and sympathoadrenal responses to hypoglycemia. They
could show that during hypoglycemia, KATP channels are
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implicated in the regulation of GABA release in this area of
the hypothalamus [131] and that an increased GABAergic
tone in the VMH contributes to suppression of counter-
regulatory responses after recurrent hypoglycemia [132]. In
addition to GABA, the excitatory neurotransmitter gluta-
mate released by VMH neurons has also been linked to the
prevention of hypoglycemia. Mice lacking synaptic vesic-
ular transporters for glutamate (VGLUT2) selectively in
SF1 neurons (a major subset of VMH neurons) exhibit
defective counter-regulatory responses during fasting as
well as to insulin- or 2-DG-induced hypoglycemia [133].
Recently, hyperinsulinemic clamp studies in humans
could show that the hypothalamus is sensitive to small
decrements in systemic glucose levels and that hypotha-
lamic blood flow and presumably neuronal activity,
precedes the rise in counter-regulatory hormones seen
during hypoglycemia [134].
There is also strong evidence that brain stem nuclei play
an important role in the control of glucagon secretion. For
instance, when the cerebral aqueduct, which allows circu-
lation of cerebrospinal fluid between the third and fourth
ventricle, is obstructed, 5-TG induces a glucoregulatory
response only when injected in the fourth but not in the
third ventricle [135]. In addition, whereas 5-TG injections
in different nuclei of the hypothalamus fail to induce a
glucoregulatory response, its injections into the NTS,
which projects to different sites of the hypothalamus,
induce a strong response [91–93]. Moreover, c-fos immu-
nostaining revealed that the activated neurons are present
in the NTS [136].
Thus, central glucose-sensing units involved in the
physiological control of counter-regulation are present at
the brain stem and the hypothalamus. These sites are
synaptically connected to form a glucose-monitoring net-
work. The gathered information is integrated to control the
counter-regulatory response by activating efferent auto-
nomic nerves that stimulate pancreatic glucagon secretion
and the secretion of epinephrine by the adrenals, and at the
same time block insulin secretion.
The role of GLUT2 and the KATP channel in the control
of glucagon secretion has been investigated in several
studies. Mice with inactivation of the Glut2 gene, while
expressing a transgenic glucose transporter (GLUT1) in
their pancreatic b-cells to preserve normal glucose-stimu-
lated insulin secretion (ripglut1::glut2-null-mice) [137]
display an abnormal increase in random fed plasma glu-
cagon levels. More importantly, ICV 2-DG injections
failed to stimulate glucagon secretion in these mutant mice
attributing a role of GLUT2-mediated central glucose
sensing also in the control of counter-regulatory processes
[40]. Furthermore, the analysis of c-fos-positive cells in
response to intraperitoneal 2-DG injections indicated a
decreased number of activated cells in the brain stem, in
particular in the NTS and the DMNX in the Glut2-null
mice. At the level of the hypothalamus, a reduced stimu-
lation of c-fos-positive cells was observed in the PVN but
not in the VMH, indicating that the glucose detection
mechanisms used to control glucagon secretion might vary
between several hypothalamic nuclei.
The involvement of KATP channel-mediated hypotha-
lamic glucose sensing in the central regulation of glucagon
secretion has also been demonstrated. For instance, the
counter-regulatory response in a hypoglycemic clamp is
blocked upon ICV or direct VMH injection of the KATP
channel inhibitor glibenclamide [55]. Genetic inactivation
of KATP channel by deletion of Kir6.2 gene also leads to
impaired glucagon response, correlated with suppressed
glucose-regulated firing activity of VMH neurons [53]. In
contrast, the activation of KATP channels in the VMH
amplifies counter-regulatory hormone responses to recur-
rent hypoglycemia [56].
The above-summarized findings clearly indicate that
central glucose sensing is implicated in a variety of impor-
tant physiological functions. In particular the coordinated
crosstalk between different sites of glucose detection allows
for the precise control of energy homeostasis and normo-
glycemia. These studies further demonstrate that there is
more than one mechanism to sense either an increase or
decrease in blood glucose levels, and that the b-cell model of
glucose sensing may have many variations.
Central lipid sensing
Cerebral lipids represent 50% of the brain dry weight,
which is the highest organ lipid content after adipose
tissue. Since neurons do not use fatty acids as a fuel, it was
thought for a long time that they are not able to cross the
blood–brain barrier. In recent years, however, it has been
demonstrated that cerebral lipids arise from both local
synthesis as well as plasma origin. Fatty acids cross the
blood–brain barrier mainly by simple diffusion in the
unbound form, so that access of circulating free fatty acids
to the CNS is proportional to their plasma concentration
[138, 139]. However, a small proportion of fatty acid
uptake into the brain may also occur through direct uptake
of lipoprotein particles mediated by lipoprotein receptors
[140, 141]. Upon entry into the cell, fatty acids are rapidly
esterified to fatty acyl-coenzyme A (acyl-CoAs) in a pro-
cess catalyzed by the enzyme acyl-CoA synthetase (ACS).
Once integrated to the intracellular acyl-CoA pool, fatty
acid fate is diverse and depends on the respective fatty
acid. For example, Rapoport et al. [141] reported that 50%
of the palmitate taken up by the brain is oxidized, whereas
80% of the arachidonate is incorporated into phospholipids.
Furthermore increasing evidence shows that fatty acids are
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used in the CNS as cellular messengers that act like glucose
to communicate the body’s energy status and thus are
involved in the control of feeding behavior, HGP, and
insulin secretion. Especially the hypothalamus is able to
detect and respond to changes in circulating fatty acid
concentrations through the involvement of lipid-sensing
neurons. Indeed, these neurons use fatty acids and their
metabolites as signaling molecules to regulate their mem-
brane potential and action potential frequency in a
concentration-dependent manner.
Lipid sensing in the hypothalamus
In 1975, Oomura et al. [142] demonstrated that fatty acids
activate neurons of the LH, indicating a role for fatty acids
as cellular messengers. Accordingly, a study using c-fos
immunoreactivity as marker for neuronal activity indicated
an activating effect of lipids on neurons located in the LH,
whereas neurons in the ARC, DMH, VMH, and PVN were
inhibited in response to lipid infusion [143]. Wang et al.
[144] demonstrated that distinct neuron populations in the
ARC modify their neuronal firing rate in response to fatty
acids and that these effects depend on ambient glucose
levels.
The molecular mechanisms involved in neuronal lipid
sensing are far from being elucidated. However, a body of
literature indicates that, in general, fatty acids regulate the
conductance of a wide variety of ion channels, which
include Cl-, GABAA [145], ClC-2 [146], K
?, K?–Ca2?,
KATP [147], and Ca
2? channels [148]. Additionally, fatty
acids inhibit the Na?–K?-ATPase [149]. Addressing
hypothalamic lipid-sensing mechanisms, Lam et al. and
Pocai et al. evidenced that the central effects of oleic acid
on liver metabolism are abolished by genetic or pharma-
cological inhibition of the KATP channel [120, 150]. Patch-
clamp recordings of oleic acid-inhibited neurons in the
ARC further supported a role for KATP channels in hypo-
thalamic lipid sensing [151]. In contrast, neuronal
excitation by oleic acid seems to be mediated by the
closure of Cl- channels [144].
The physiological relevance of lipid sensing is sup-
ported by various studies. For instance, intravenous
infusion of a lipid emulsion is sufficient to suppress food
intake in baboons [152]. This signal is independent of
measurable changes in plasma insulin and does not require
gastrointestinal nutrient absorption [152–155]. Consistent
with the hypothesis that circulating lipids act on hypotha-
lamic energy centers to generate a signal of nutrient surfeit,
the group of Rossetti and colleagues demonstrated that ICV
administration of the long-chain fatty acid (LCFA) oleic
acid inhibits food intake and leads to a decrease in HGP
[156, 157]. Interestingly, using the same protocol octanoic
acid, a medium-chain fatty acid had no effect, suggesting
that fatty acid action is related to the respective chain
length. The authors attributed the anorectic effect of oleic
acid to its action on orexigenic ARC neuropeptide
expression, i.e., reduction of AgRP and NPY mRNA
expression, whereas POMC expression was not affected by
oleic acid treatment. In the liver, ICV oleic acid inhibited
the expression of glucose-6-phosphatase, the rate-limiting
gluconeogenic enzyme [156, 157].
A decrease in food intake and HGP is also obtained by
inhibiting hypothalamic carnitine palmitoyltransferase
(CPT) 1 [158]. These effects on food intake and HGP were
proposed to be caused by the accumulation of intracellular
LCFA-CoA due to the inhibition of CPT1-mediated mito-
chondrial import of LCFA-CoA for b-oxidation. This
finding suggests that an increase in intracellular LCFA-
CoA concentrations, rather than fatty acids themselves, is
the ‘‘final’’ satiety signal that activates neural pathways
designed to regulate the input of nutrients in the circulation
from either exogenous (food intake) or endogenous sources
(HGP) [158–160]. Indeed, a sustained two-to-threefold
elevation in circulating long-chain fatty acid levels is
sufficient to double LCFA-CoA concentrations within the
mediobasal hypothalamus. Furthermore, this increase is
prevented by intrahypothalamic infusion of triascin C, a
pharmacological inhibitor of LCFA-CoA synthetase [150].
The inhibition of hypothalamic LCFA-CoA synthetase
activity also abolishes the ability of circulating LCFA to
suppress HGP, indicating that hypothalamic esterification
of LCFA to LCFA-CoA is required for the observed effects
of LCFA on liver metabolism [150]. However, it has to be
noted that inhibition of CPT1 leads to increased levels of
LCFA-CoA in the ARC, but not in other hypothalamic
nuclei [158], and inhibition of b-oxidation in the LH does
not alter food intake [161].
The role of hypothalamic fatty acid metabolism
Fatty acid metabolism seems crucial to relay the central
action of fatty acids on energy homeostasis. Enzymes
involved in fatty acid metabolism, such as acetyl-CoA
carboxylase (ACC), fatty acid synthase (FAS), malonyl-
CoA decarboxylase (MCD), and CPT1 are expressed in
various brain cell types including hypothalamic neuron
populations in the ARC, VMH, and dorsomedial hypo-
thalamus [162]. Furthermore, double-labeling studies have
shown that FAS colocalizes with NPY (and thus AgRP) in
ARC neurons [163], indicating that modulation of fatty acid
synthesis may act on hypothalamic pathways regulating
feeding. Feeding increases the concentration of cytoplasmic
malonyl-CoA, which is suggested to be one of the main
energy sensors in the hypothalamus. Accumulation of
malonyl-CoA derives from an increased flux of glucose
into the lipogenic pathway during the fed state, i.e., when
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nutrients are abundant. The steady-state level of malonyl-
CoA is determined by its rate of synthesis catalyzed by
ACC relative to its rate of turnover catalyzed by FAS. The
synthesis of malonyl-CoA is the first step of fatty acid
synthesis and ACC is the major site of regulation. In addi-
tion, malonyl-CoA is a potent inhibitor of CPT1 and thereby
b-oxidation. Thus, in times of ample energy supply, when
there is a decreased need for fatty acid oxidation, increased
malonyl-CoA levels may inhibit b-oxidation and increase
fatty acid synthesis and esterification to triglycerides.
Consistent with a role for neuronal FAS in the modu-
lation of feeding, central administration of C75, a potent
inhibitor of FAS, increases malonyl-CoA concentrations in
the hypothalamus, suppresses food intake and leads to
profound weight loss [164, 165]. In mice deprived of food,
central administration of C75 at anorexic doses also sig-
nificantly increases hypothalamic malonyl-CoA levels
[166]. Moreover, pharmacological inhibition of ACC, and
thereby malonyl-CoA synthesis, largely reverses the effect
of C75 on feeding and malonyl-CoA accumulation
[164, 166], supporting the idea that malonyl-CoA avail-
ability is essential for the hypothalamic control of food
intake. In vitro and in vivo studies demonstrate that at least
parts of C75’s effects are mediated through AMPK [167,
168]. Indeed, ICV administration of 5-aminoimidazole-
4-carboxamide-ribonfuranoside (AICAR), an AMPK
activator, rapidly lowers hypothalamic malonyl-CoA con-
centrations, increases food intake, and also attenuates
C75-induced anorexia [167, 169]. These effects correlate
closely with the phosphorylation and thus inactivation of
ACC, an established AMPK target.
The anorectic action of FAS inhibition is linked to
decreased expression of orexigenic and increased expression
of anorexigenic neuropeptides in the ARC, as central
administration of C75 blocks fasting-induced up-regulation
of AgRP/NPY and down-regulation of POMC/CART
expression [164–166, 170]. The molecular mechanisms
underlying these effects of FAS inhibition are not com-
pletely understood. It has been reported that changes in
hypothalamic malonyl-CoA levels correlate with C75’s
effects on neuropeptide expression [166]. However, it is so
far unclear how accumulation of malonyl-CoA is linked to
changes in neuropeptide gene expression and whether its
effects are direct or indirect via inhibition of CPT1 and the
ensuing accumulation of LCFA-CoA. The latter is supported
by the anorectic action of both hypothalamic inhibition of
CPT1 [158] and central administration of LCFA [156, 157].
Interrelationship between glucose and lipid sensing
It is well known from pancreatic islets that glucose and
lipid sensing are interrelated, since elevated fatty acid
concentrations are able to modify the secretory response to
glucose [171, 172]. This has been attributed to the intra-
cellular accumulation of various lipid metabolites that
interfere with the function of ion channels or other proteins
regulating the exocytosis of insulin granules [173]. More-
over, free fatty acids have been demonstrated to decrease
the expression of key components of the glucose-signaling
pathway such as GLUT2 and glucokinase [174]. There is
now also increasing evidence that elevated concentrations
of fatty acids may induce ER stress that, under chronic
conditions, exerts deleterious effects on pancreatic islet
cells [175].
The observation that anorexia resulting from FAS inhi-
bition is dependent on changes in central glucose uptake
and/or metabolism [176] supported the idea that nutrient-
sensing pathways are also interconnected in the brain. High
glucose levels are known to elevate intracellular malonyl-
CoA, which in turn inhibits CPT1 and thereby b-oxidation.
Increased levels of malonyl-CoA may in turn induce
an increase in glucose oxidation as a consequence of
decreasing fatty acid oxidation. Thus, the CNS may use the
relative ratio of glucose to fatty acid utilization as an index
of the overall energy status of the body [176]. Further
points of interaction between glucose and lipid metabolism
are KATP channels and AMPK (Fig. 2). Increased glucose
oxidation raises intracellular ATP levels, which leads to the
closure of KATP channels. These channels also seem to be
affected by intracellular accumulation of LCFA-CoA [120,
150]. Finally, a decrease in glucose concentration activates
AMPK, which phosphorylates and thereby inhibits ACC,
thus reducing malonyl-CoA formation and increasing
b-oxidation.
Electrophysiological evidence for a direct functional
interaction of central lipid and glucose sensing in the
hypothalamus has been provided by measuring the firing
rate of ARC and VMH neurons in response to oleic acid in
the presence of different ambient glucose concentrations
[144, 177]. These data revealed an interaction between
glucose and fatty acids to regulate oleic acid sensing in
neurons of these hypothalamic nuclei, implying that sub-
types of lipid-sensing neurons are activated or inhibited,
depending on the hypo-, normo- or hyperglycemic status.
Even more interesting in this context is the proposed role
for reactive oxygen species (ROS) signaling in glucose
and lipid sensing by AgRP/NPY and POMC neurons
[178–180]. ROS production naturally occurs during mito-
chondrial respiration of products resulting from both
glucose and fatty acid metabolism and thus may represent
an additional interconnection of neuronal nutrient sensing.
This notion is further supported by an increasing number of
studies indicating that ROS production is not simply a
byproduct of substrate oxidation but, instead, is implicated
in the regulation of neuronal function in a substrate-
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dependent manner [179–182]. Andrews et al. observed that
during positive energy balance, glucose-excited POMC
neurons accumulate ROS due to increased glucose utili-
zation. Contrariwise, during negative energy balance, when
low glucose levels activate AgRP/NPY neurons, elevated
fatty acid oxidation in these cells does not increase intra-
cellular ROS levels. Endogenous buffering of ROS
production seems to be indispensable for the function of
AgRP/NPY neurons, since uncontrolled ROS formation
impairs neuronal firing of these cells. Thus, persistent high
ROS levels in active POMC neurons seem to favor satiety
during energy surplus, whereas in active AgRP/NPY neu-
rons ROS production needs to be buffered to allow for the
appropriate orexigenic responses to energy deficiency [180,
183].
Hormonal modulation of glucose and lipid sensing
Apart from influencing each other, hypothalamic glucose
and lipid sensing is controlled by peripheral hormones,
such as insulin, leptin, and ghrelin. The central actions of
these hormones comprise several sites of convergence with
nutrient sensing, as, for instance, in the ARC, they regulate
neuronal activity of glucose-excited POMC as well as
glucose-inhibited AgRP/NPY neurons [2, 14, 184].
The finding that central applied insulin decreases food
intake and body weight led to the proposal that insulin
serves as an adiposity signal in the brain, decreasing food
intake and increasing energy expenditure [185–187]. Along
these lines, mice with brain-specific insulin receptor dele-
tion are mildly obese and display impaired fertility,
assigning insulin receptor signaling in the brain a role in
regulation of fuel metabolism and reproduction [188].
Importantly, insulin action in the brain not only controls
body weight [185, 188–190] but also peripheral glucose
and fat metabolism [191–193]. Insulin’s central action in
controlling food intake and hepatic gluconeogenesis is
mediated by the activation of the PI3 kinase and sub-
sequent regulation of KATP channel activity by its product
PIP3 [105, 192, 194]. Thus, KATP channel activation might
represent a mechanism allowing for integration of hor-
monal and nutrient (glucose)-dependent modulation of
glucose and lipid sensing in the hypothalamus (Fig. 2).
This notion is supported by the recent finding that insulin
attenuates the ability of VMN GE neurons to sense
decreased glucose via the activation of PI3 kinase and
KATP channels [195]. These data are consistent with the
role of insulin as satiety factor, as in the presence of insulin
glucose levels must decline to a greater extend before GE
neurons respond.
Similarly, the adipocyte-derived hormone leptin, which
is secreted in proportion to the body fat content [196, 197],
has provided the prototypic adiposity signal in the control
of energy homeostasis [198]. Mice carrying a mutation in
the leptin gene (ob) exhibit dramatic weight gain (ob/ob)
[198], and a naturally occurring loss-of-function mutation
of the leptin receptor in the CNS and periphery underlies
the phenotype of obese and diabetic mice (db/db) [199].
Importantly, the phenotype of mice with a neuron-specific
deletion of the leptin receptor resembles that of the db/db
mouse [200], and neuron-specific reconstitution of the
leptin receptor is sufficient to reverse the obese phenotype
of db/db mice [201], indicating that indeed the major role
of leptin action to control energy homeostasis is accounted
for by its signaling in the CNS. Consistent with this, central
application of leptin decreases food intake and body weight
in various species, underlining the pivotal role of leptin in
the regulation of energy homeostasis via its action in the
CNS [202]. Moreover, leptin, via activation of the CNS PI3
kinase pathway, is crucial for the regulation of glucose
metabolism and peripheral insulin sensitivity [105, 203–
207]. Leptin has been shown to inhibit hypothalamic
AMPK activity [208]. Furthermore, expression of a con-
stitutively active AMPK mutant in the hypothalamus blunts
leptin’s effects on food intake, thus indicating that AMPK
serves as a principal mediator of leptin’s effects on food
intake and fatty-acid metabolism [26, 209, 210]. Since
AMPK is also inhibited by insulin [208], regulation of
Fig. 2 Crosstalk and hormonal regulation of glucose and lipid
sensing. This schematic representation of the interrelationship
between glucose and lipid-sensing mechanisms and their modulation
by hormones underlines the convergence of these signals on three key
players: AMPK, malonyl-CoA, and KATP channels. LCFA-CoA long-
chain fatty acyl-CoA, ACC acetyl-CoA carboxylase, FAS fatty acid
synthase, CPT1 carnitine palmitoyltransferase 1
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hypothalamic AMPK activity represents a further site of
convergence between hormonal and nutritional control of
neuron excitability (Fig. 2).
However, studies in mice lacking a functional AMPKa2
subunit specifically in either AgRP or POMC neurons
suggest differential mechanisms for glucose sensing and
leptin-/insulin-stimulated pathways, since these neurons
were still responsive to both insulin and leptin but not
glucose [110]. Conversely, Murphy et al. [211] recently
demonstrated that leptin-induced changes in glucose sens-
ing of NPY-expressing GI neurons are mediated by AMPK
and concluded that during energy sufficiency, leptin redu-
ces the ability of AgRP/NPY neurons to sense decreased
glucose concentrations.
AMPK activity is further regulated by ghrelin, an
orexigenic gut hormone, which is released to the circula-
tion upon fasting [212, 213]. In the arcuate nucleus, ghrelin
activates AgRP/NPY neurons, thereby mediating its orex-
igenic effect [214]. In addition to its stimulatory effect on
food intake, centrally applied ghrelin, presumably via
control of sympathetic innervation, influences adipocyte
metabolism [215]. Central ghrelin induces AMPK activity
via the activation of Ca2? signaling and subsequent acti-
vation of CamKK2 in NPY neurons [216–218]. The
following chain of intracellular events seems to contribute
to ghrelin’s effect on AgRP/NPY neurons. AMPK inhibits
ACC activity, thereby eliminating the inhibitory effect of
malonyl-CoA on CPT1 activity. CPT1 activation enhances
mitochondrial b-oxidation of long-chain fatty acids, which
ultimately promotes generation of reactive oxygen species
(ROS). Fatty acids and ROS promote UCP2 transcription
and activity, which aims to neutralize ROS, thereby
enabling continuous CPT1-promoted fatty acid b-oxida-
tion. Moreover, UCP2 can increase NPY/AgRP neuronal
activity, thereby increasing inhibitory GABA-ergic input
onto POMC neurons, ultimately stimulating food intake
[180, 219].
Taken together, these findings clearly point towards a
convergence between hypothalamic nutrient sensing and
hormone signaling in order to maintain energy homeostasis
via the integration of multiple signals.
Fuel sensing in obesity and type 2 diabetes mellitus
Since peripheral nutrient sensing and its dysregulation
represent key components of diet-induced obesity and
diabetes mellitus, impaired fuel sensing in the CNS,
especially the hypothalamus, may also be involved in the
development of high-fat-diet-induced obesity and periph-
eral insulin resistance. In peripheral tissues, sustained
exposure to a supply of nutrients that exceeds energy
requirements induces insulin resistance via multiple,
convergent mechanisms [220]. Given the diversity of tis-
sues affected by nutrient excess, it is not surprising that
resistance to the actions of both insulin and leptin in the
CNS represents a hallmark during the development of
high-caloric-diet-induced weight gain and peripheral insu-
lin resistance [190]. However, this response has the
potential to cause obesity, rather than simply being its
consequence, because insulin and leptin are crucial hor-
monal signals that convey adiposity negative feedback
information to the hypothalamus regarding the amount of
body fuel stored in the form of fat. When input from these
hormones is reduced, this triggers an adaptive increase of
food intake that favors body weight gain. Consistently,
high-fat-diet-induced obesity reduces the ability of intra-
cerebroventricularly applied insulin, leptin, and LCFA to
reduce food intake and glucose production [157, 221–224].
These effects are also present in rats fed a high-fat diet that
are calorically and body weight matched to rats on a low-
fat diet [222]. Moreover, exposing the animals to a normal
chow diet can restore high-fat-feeding-induced leptin
resistance in mice, even before body weight has been
normalized [225]. Taken together, these data indicate that
diet-induced leptin and insulin resistance in the CNS may
be caused directly by food components, rather than obesity
per se.
Indeed, saturated fatty acids, such as palmitate, which is
also increased in the hypothalamus upon high-fat feeding
[226], acutely causes leptin resistance in the CNS [227].
Saturated fatty acids represent important candidates for
causing diet-induced leptin and insulin resistance, they act
as ligands for Toll-like receptor 4 (TLR4) [228], thus
activating JNK- and IKK-signaling cascades, both of which
inhibit insulin action in peripheral tissues such as skeletal
muscle, liver, and adipose tissue [229] as well as in the
hypothalamus [230–232]. In the hypothalamus, pro-
inflammatory signaling via TLRs not only inhibits neuronal
insulin action but can also inhibit leptin signal transduction
to further aggravate obesity [227, 233–235]. Consistently,
the ability of a high-fat diet to induce obesity and its
associated metabolic derangements depends upon neuronal
expression of MyD88, a key intracellular mediator of
inflammatory signaling [227].
Obesity also correlates with altered hypothalamic
glucose sensing, as obese Zucker rats display central glu-
cose hypersensitivity, which has recently been linked
to mitochondrial dysfunction leading to changes in redox
signaling [236].
A better understanding of the mechanisms by which
high-caloric diets and and/or the resulting obesity reduce
central sensitivity to peripheral hormonal and nutritional
signals may allow for the development of potential novel
pharmacological targets for the treatment of obesity
and type 2 diabetes mellitus. Nevertheless, many aspects
Glucose and lipid sensing in the brain 3265
regarding the extra- and intracellular mechanisms that
contribute to CNS nutrient and hormonal resistance are still
elusive and further investigations will have to unravel the
complex network of the CNS in sensing nutrients and
transmitting their effects.
Concluding remarks
The global prevalence of obesity and diabetes mellitus is
increasing at an alarming rate and dysregulation of the
central control of energy homeostasis has been posited as a
causative mechanism of these metabolic diseases. Besides
the capability of selective brain regions, especially the
hypothalamus, to integrate a variety of neuronal and hor-
monal signals, increasing evidence indicates that fuel
sensing also plays a pivotal role in the central regulation of
food intake, energy expenditure, and glucose homeostasis.
Recent progress has confirmed the presence of distinct
hypothalamic neuron populations that respond to changes
in circulating nutrient concentrations by either activating or
inhibiting their firing activity. At the molecular level, some
proteins required for neuronal fuel sensing have already
been identified. Among them, KATP channels and the well-
known fuel sensor AMPK represent critical points of
interaction between hypothalamic glucose and lipid sens-
ing. A wide range of data further implicates the modulation
of neuronal fuel sensing by a variety of hormones such as
insulin, leptin, and ghrelin, leading to an increased degree
of complexity in the response of these neurons to changes
in whole-body energy level. Beyond the scope of this
review is another relative new concept in central nutrient
sensing involving the role of amino acids in the regulation
of energy homeostasis. Studies have demonstrated that
increasing or decreasing the dietary intake of leucine, a
branched-chain amino acid, as well as ICV administration
of this amino acid affects glucose metabolism and food
intake [237, 238]. The latter was attributed to changes in
hypothalamic AgRP expression and mechanistically linked
to mammalian target of rapamycine (mTOR) [237, 239].
A better understanding of the complex interaction of
nutrients, hormones, and neuronal circuitries in the mod-
ulation of central behavioral and metabolic output signals
might point to novel interventions to prevent or treat
obesity and type 2 diabetes mellitus.
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